Metraipolis › archive › dc_987aeb0b852f
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody — Europe PMC PMID:38635853
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38635853
- DOI
- 10.1371/journal.ppat.1011680
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T18:47:29.594Z
- SHA-256 of the archived text
0fa60cc5b268e7ef1f9b83d7b4757c67699ca5d0c4443685874546d618f84e7e- Stable URL of this page
https://metraipolis.com/documento/dc_987aeb0b852f
How to cite
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody — Europe PMC PMID:38635853 — Europe PMC (en), https://europepmc.org/article/MED/38635853 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_987aeb0b852f (Metraipolis archive dc_987aeb0b852f, sha256 0fa60cc5b268e7ef1f9b83d7b4757c67699ca5d0c4443685874546d618f84e7e)
BibTeX
@misc{dc987aeb0b852f,
title = {Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody — Europe PMC PMID:38635853},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38635853},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_987aeb0b852f; sha256 0fa60cc5b268e7ef1f9b83d7b4757c67699ca5d0c4443685874546d618f84e7e},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38635853. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
To mitigate the loss of lives during the COVID-19 pandemic, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of the virus and block its ability to enter and infect target cells. Monoclonal antibody therapy can thus accelerate the decline in viral load and lower hospitalization rates among high-risk patients with variants susceptible to mAb therapy. However, viral resistance has been observed, in some cases leading to a transient viral rebound that can be as large as 3-4 orders of magnitude. As mAbs represent a proven treatment choice for SARS-CoV-2 and other viral infections, evaluation of treatment-emergent mAb resistance can help uncover underlying pathobiology of SARS-CoV-2 infection and may also help in the development of the next generation of mAb therapies. Although resistance can be expected, the large rebounds observed are much more difficult to explain. We hypothesize replenishment of target cells is necessary to generate the high transient viral rebound. Thus, we formulated two models with different mechanisms for target cell replenishment (homeostatic proliferation and return from an innate immune response antiviral state) and fit them to data from persons with SARS-CoV-2 treated with a mAb. We showed that both models can explain the emergence of resistant virus associated with high transient viral rebounds. We found that variations in the target cell supply rate and adaptive immunity parameters have a strong impact on the magnitude or observability of the viral rebound associated with the emergence of resistant virus. Both variations in target cell supply rate and adaptive immunity parameters may explain why only some individuals develop observable transient resistant viral rebound. Our study highlights the conditions that can lead to resistance and subsequent viral rebound in mAb treatments during acute infection. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2024 (prima pubblicazione 2024-04-18). Identificativi: PMID 38635853 · PMCID PMC11060554 · DOI 10.1371/journal.ppat.1011680. Descrittori MeSH principali: Antibodies, Monoclonal; Spike Glycoprotein, Coronavirus; COVID-19; SARS-CoV-2; COVID-19 Drug Treatment. Pagina: https://europepmc.org/article/MED/38635853 — https://doi.org/10.1371/journal.ppat.1011680. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T17:12:53.297Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.